Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text

Medicine, Immunology, Oncology +17

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Medicine, Gynecology, Oncology +16

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

Medicine, Gynecology, Oncology +11

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda et al. · Journal of Clinical Oncology · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +17

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

M. E. Christine Lutsiak, Roshanak Tolouei Semnani, Roberto De Pascalis et al. · Blood · 2005 · 896 citations · Full text

Life Sciences, Immunology, Pharmacology +16